3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
19
Lung Neoplasms
6
Solid Tumor
1
Small Cell Lung Carcinoma
1
Resectable Non-small Cell Lung Cancer
1
Recurrence
1
Rare Tumour
1
Neoplastic Cells, Circulating
1
Neoplasm, Residual
1
NSCLC
1
Meningeal Carcinomatosis
1
Brain Neoplasms
1
Interventions
Etoposide
15
Carboplatin
14
Cisplatin
9
anlotinib
8
PM 01183
6
toripalimab
5
Drug Therapy
5
tislelizumab
4
atezolizumab
4
Topotecan
4
Radiotherapy
4
Platinum
4
irinotecan sucrosofate
3
durvalumab
3
famitinib
2
apatinib
2
Pemetrexed
2
Paclitaxel
2
EC regimen
2
sintilimab
1
osimertinib
1
nintedanib
1
fludarabine
1
amrubicin
1
Tomography, X-Ray Computed
1
Tissue Banks
1
Radiation Dose Hypofractionation
1
Rabeprazole
1
Proton Pump Inhibitors
1
Platinum Compounds
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Not yet recruiting
×
Small Cell Lung Carcinoma
×
osimertinib
×
Clear all
NCT07153055
2025-12-18
LOTS
Indiana University
Phase 1/2
Not yet recruiting
16 enrolled